| Targeting neoantigens to augment antitumour immunity M Yarchoan, BA Johnson III, ER Lutz, DA Laheru, EM Jaffee Nature Reviews Cancer 17 (4), 209-222, 2017 | 1046 | 2017 |
| Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2, 3 dioxygenase AJ Muller, MD Sharma, PR Chandler, JB DuHadaway, ME Everhart, ... Proceedings of the National Academy of Sciences 105 (44), 17073-17078, 2008 | 291 | 2008 |
| Strategies for increasing pancreatic tumor immunogenicity BA Johnson III, M Yarchoan, V Lee, DA Laheru, EM Jaffee Clinical Cancer Research 23 (7), 1656-1669, 2017 | 155 | 2017 |
| Dendritic cells, indoleamine 2, 3 dioxygenase and acquired immune privilege L Huang, B Baban, BA Johnson III, AL Mellor International reviews of immunology 29 (2), 133-155, 2010 | 149 | 2010 |
| Physiologic control of IDO competence in splenic dendritic cells B Baban, PR Chandler, BA Johnson, L Huang, M Li, ML Sharpe, ... The Journal of Immunology 187 (5), 2329-2335, 2011 | 95 | 2011 |
| Targeting the immunoregulatory indoleamine 2, 3 dioxygenase pathway in immunotherapy BA Johnson 3Rd, B Baban, AL Mellor Immunotherapy 1 (4), 645-661, 2009 | 86 | 2009 |
| Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer M Yarchoan, MC Myzak, BA Johnson III, A De Jesus-Acosta, DT Le, ... Oncotarget 8 (27), 44073, 2017 | 77 | 2017 |
| B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2, 3-dioxygenase BA Johnson III, DJ Kahler, B Baban, PR Chandler, B Kang, M Shimoda, ... Proceedings of the National Academy of Sciences 107 (23), 10644-10648, 2010 | 54 | 2010 |
| A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive … NM Hahn, MA O'Donnell, JA Efstathiou, M Zahurak, GL Rosner, J Smith, ... European urology 83 (6), 486-494, 2023 | 25 | 2023 |
| Enfortumab vedotin–related cutaneous toxicity and radiographic response in patients with urothelial cancer: A single-center experience and review of the literature E Vlachou, A Matoso, D McConkey, Y Jing, BA Johnson 3rd, NM Hahn, ... European Urology Open Science 49, 100-103, 2023 | 17 | 2023 |
| New and topics: Enfortumab vedotin mechanisms of response and resistance in urothelial cancer–what do we understand so far? J Hoffman-Censits, K Lombardo, D McConkey, NM Hahn, B Bashir, ... Urologic oncology: Seminars and original investigations 39 (10), 619-622, 2021 | 13 | 2021 |
| pAKT expression and response to sorafenib in differentiated thyroid cancer M Yarchoan, C Ma, AB Troxel, SJ Stopenski, W Tang, AB Cohen, ... Hormones and Cancer 7, 188-195, 2016 | 11 | 2016 |
| Gender-specific stratification of survival following immune checkpoint inhibitor therapy based on intratumoral expression of a B cell gene signature AK Aragaki, Y Jing, J Hoffman-Censits, W Choi, NM Hahn, BJ Trock, ... European Urology Oncology 5 (3), 338-346, 2022 | 9 | 2022 |
| Lentiviral interferon: A novel method for gene therapy in bladder cancer S Mokkapati, VM Narayan, GC Manyam, AH Lim, JJ Duplisea, ... Molecular Therapy-Oncolytics 26, 141-157, 2022 | 6 | 2022 |
| Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): Real-world experience. E Vlachou, NM Hahn, A Dabb, BA Johnson, MS Lefande, ... Journal of Clinical Oncology 41 (6_suppl), 523-523, 2023 | 4 | 2023 |
| Relationship of lymphocyte and eosinophil counts and immune-related adverse events in recipients of programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective … A Diehl, M Yarchoan, T Yang, B Scott, BA Johnson, A Hopkins, NS Azad, ... Journal of Clinical Oncology 35 (15_suppl), e14586-e14586, 2017 | 4 | 2017 |
| Relationship between lymphopenia and objective response rate with programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis. M Yarchoan, A Diehl, BA Johnson, B Scott, A Hopkins, NS Azad, ... Journal of Clinical Oncology 35 (15_suppl), e14512-e14512, 2017 | 3 | 2017 |
| Clinicopathologic and survival after cystectomy outcomes in squamous cell carcinoma of the bladder P Agrawal, M Rostom, R Alam, I Florissi, M Biles, K Rodriguez, NM Hahn, ... Clinical Genitourinary Cancer 21 (6), 631-638. e1, 2023 | 2 | 2023 |
| Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience E Vlachou, BA Johnson 3rd, D McConkey, Y Jing, A Matoso, NM Hahn, ... Frontiers in Oncology 14, 1377842, 2024 | 1 | 2024 |
| Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer E Vlachou, BA Johnson III, E Baraban, R Nadal, J Hoffman-Censits American Society of Clinical Oncology Educational Book 44 (3), e438640, 2024 | 1 | 2024 |
